STOCK TITAN
  1. Home
  2. Sec-filings
  3. SVA
  4. [6-K] SINOVAC BIOTECH LTD Current Report (Foreign Issuer)

Sinovac extends deadline for $55 special dividend

Sinovac Biotech Ltd. extended the deadline for shareholders and nominee brokers to submit payment instructions for its previously declared special cash dividend of US$55.00 per common share.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Sinovac Biotech Ltd. extended the deadline for shareholders and nominee brokers to submit payment instructions for its previously declared special cash dividend of US$55.00 per common share. The dividend is payable to valid holders of common shares as of the close of business on May 23, 2025 ET.

Instruction materials were originally due by December 31, 2025, then extended to June 30, 2026, and are now further extended to December 31, 2026 to facilitate payment of the dividend. Shareholders with questions are directed to the Information Agent, D.F. King & Co., Inc., or Sinovac’s investor relations contacts.

Positive

  • None.

Negative

  • None.
Special cash dividend US$55.00 per common share Previously declared special cash dividend payable to valid holders of common shares
Dividend record date May 23, 2025 Close of business on May 23, 2025 ET for determining valid holders eligible for the dividend
Original instruction deadline December 31, 2025 Initial deadline for submitting payment instruction materials for the special dividend
First extended deadline June 30, 2026 First extension of the deadline to submit dividend payment instructions
Current instruction deadline December 31, 2026 Current extended deadline for shareholders and nominee brokers to submit payment instructions
special cash dividend financial
"special cash dividend of US$55.00 per common share, payable to valid holders"
A special cash dividend is a one-time, extra cash payment a company gives to its shareholders in addition to its regular dividends, like a bonus check sent out when a business has more cash than usual. It matters to investors because it delivers immediate cash value, can signal that the company has strong short-term cash or limited opportunities to reinvest, and typically reduces the company’s cash reserves and may affect the stock price and tax treatment for recipients.
Information Agent regulatory
"If you have any questions ... please contact the Information Agent D.F. King & Co., Inc."
An information agent is a person, team, or third-party service designated to collect, verify and distribute a company’s important announcements, filings or notices to regulators, shareholders and the public. Think of it as the company’s official mailroom and translator combined—responsible for making sure the right facts get to the right people quickly and accurately; investors watch who serves this role because mistakes or delays can affect compliance, market reaction and trust.
biopharmaceutical medical
"a leading provider of biopharmaceutical products in China"
A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.
prequalified by WHO medical
"of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine"
Sabin-strain inactivated polio vaccine (sIPV) medical
"including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV)"

FAQ

What did Sinovac Biotech (SVA) change regarding its special cash dividend?
Sinovac Biotech extended the deadline for shareholders and nominee brokers to submit payment instructions for its special cash dividend. Instructions, previously due June 30, 2026, are now accepted until December 31, 2026 to help ensure eligible holders can receive their payments.

How much is Sinovac Biotech (SVA) paying in its special cash dividend?
Sinovac declared a special cash dividend of US$55.00 per common share. This amount applies to valid holders of the company’s common shares as of the close of business on May 23, 2025 ET, subject to shareholders completing the required payment instruction process.

Who is eligible to receive Sinovac Biotech (SVA)’s special cash dividend?
The dividend is payable to valid holders of Sinovac common shares as of the close of business on May 23, 2025 ET. These shareholders must ensure their payment instruction materials are properly completed and submitted by the extended deadline to facilitate receiving the dividend.

What is the new deadline to submit Sinovac (SVA) dividend payment instructions?
Sinovac has extended the submission deadline for dividend payment instructions to December 31, 2026. Instruction materials originally due by December 31, 2025, and then June 30, 2026, can now be submitted through the end of 2026 to help complete dividend payments.

Who should Sinovac Biotech (SVA) shareholders contact about the special dividend process?
Shareholders with questions about the special dividend should contact the Information Agent, D.F. King & Co., Inc., at its New York office or email sva@dfking.com. Investors may also reach Sinovac Biotech’s investor relations at ir@sinovac.com or by telephone in Beijing.

Does the Sinovac (SVA) announcement create a new dividend or change the record date?
The announcement does not create a new dividend or change the record date. It only extends the deadline for submitting payment instructions for the previously declared US$55.00 per share special cash dividend payable to holders as of May 23, 2025 ET.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

 

 

Commission File Number: 001-32371

 

 

 

SINOVAC BIOTECH LTD.

 

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒                 Form 40-F ☐

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SINOVAC BIOTECH LTD.
     
  By: /s/ Nan Wang
  Name: Nan Wang
  Title: Chief Financial Officer

 

Date: July 15, 2026

 

1

 

Exhibit Index

 

Exhibit 99.1   Press Release

 

2

 

Exhibit 99.1

 

 

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

 

2026-07-15

 

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend.

 

The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company previously extended that submission deadline to June 30, 2026, and has now further extended that submission deadline to December 31, 2026.

 

Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before December 31, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to undertake to receive the Dividend, please contact the Information Agent:

 

D.F. King & Co., Inc.

28 Liberty Street, 53rd Floor

New York, NY 10005

Attention: Sinovac Biotech Ltd. Special Dividend

Email: sva@dfking.com, with a subject line of Sinovac Biotech Ltd, Special Dividend

 

Contact

 

Sinovac Biotech Ltd.

 

Helen Yang
Tel: +86-10-8279 9720
Email: ir@sinovac.com

 

 

 

About SINOVAC

 

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

 

The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

 

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

 

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

 

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

 

For more information, please see the Company’s website at www.sinovac.com.

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases